Chemical Pathology Flashcards
3 most important buffering systems in the body
Bicarbonate (ECF, glomerular filtrate) H + HCO3
Haemoglobin (red cells) H + Hb
Phosphate (renal tubular cells / intracellular) H + HPO4
How are bicarbonate ions regenerated?
Reaction of water and carbon dioxide produces carbonic acid which generates a bicarbonate ion. The bicarbonate ion can then be reabsorbed in the proximal tubule.
NB: The hydrogen ion produced is excreted through a hydrogen/sodium pump (exchanged with sodium).
How to calculate bicarbonate?
[H+] = (k x [CO2]) / [HCO3-]
NB: on a blood gas, bicarbonate is calculated not measured
Causes of metabolic acidosis
- Increased H+ production eg. DKA, lactic acidosis (decreased blood supply)
- Decreased H+ excretion eg. renal tubular acidosis
- Bicarbonate loss eg. intestinal fistula
Causes of respiratory acidosis
Decreased ventilation
Poor lung perfusion
Impaired gas exchange eg. PE, emphysema
(primary abnormality is increased CO2 which drives reaction to left, increasing hydrogen ion concentration)
Causes of metabolic alkalosis
Hydrogen ion loss eg. pyloris stenosis or vomiting
Hypokalaemia (Na/K/H+ pump)
Ingestion of bicarbonate
Causes of respiratory alkalosis
Due to hyperventilation which can be caused by:
Voluntary
Artificial ventilation
Stimulation of respiratory centre (rare drugs)
Compensation for chronic respiratory alkalosis
Kidney excretion of hydrogen ions decreases so hydrogen ion increases. On blood gas:
pH starts to normalise
CO2 and HCO3- remain low
What does deficient enzyme activity lead to?
Lack of end product
Build-up of precursors
Abnormal, often toxic metabolites (high concentrations of precursors causes activation of enzymes that may not usually be active for these substrates in their low concentrations)
IMD Screening Criteria
(Wilson & Junger 1968)
- Important health problem
- Accepted treatment
- Facilities for diagnosis and treatment
- Latent or early symptomatic stage
- Suitable test or examination
- Test should be acceptable to population
- Natural history understood
- Agreed policy on whom to treat as patients
- Economically balanced
- Continuing process
Classical Phenylketonuria (PKU)
Low IQ (<50)
Common 1:5000 to 1:50000
Over 400 gene mutations
Treatment only effective if started within first 6 weeks of life
Sensitivity & Specificity
Sensitivity = proportion of people with true presence of disease (out of everyone who has disease, how many tested positive?)
Specificity = proportion of people with true absence of disease
Positive & Negative predictive Value
PPV = out of everyone who tested positive, how many actually have disease?
NPV = out of everyone who tested negative, how many actually don’t have disease?
Depends on disease prevalence/incidence
UK Screening for IMD
Carried out in first 5-8 days of life
Heel-prick capillary from posterior medial third of foot, blood is spotted onto Guthrie card (thick filter paper)
Bloodspot card sent to specialist lab, bloodspots are punched out, blood sample eluted and phenylalanine measured.
PPV for classic PKU = 80%
UK screening for congenital hypothyroidism
incidence 1:4000
inherited only 15%
usually dysgenesis/agenesis of thyroid gland
not always detected clinically but may have puffy face, skin mottling, large tongue, umbilical hernia, hoarse cry
based on high TSH
PPV 60-70%
treatable with thyroxine
Why was CF added to UK screening programme?
Irrefutable evidence that early intervention improves outcome
Cystic Fibrosis pathology
6 classes of defect
failure of chloride ion movement from inside epithelial cell into lumen leading to increased absorption of sodium and water resulting in viscous secretions and doctule blockage
Manifestations of CF
Lungs: recurrent infection
Pancreas: malabsorption, steatorrhoea, diabetes
Liver: cirrhosis
Neonatal test for CF
high blood immune reactive trypsin (IRT)
if level is above 99.5th (70ng/mL) centile in 3 bloodspots, do DNA mutation detection (panel of 4)
2 mutations = diagnosis of CF
1 mutation -> expand panel to 28, and if another mutation is detected -> diagnosis of CF
0 mutations -> another IRT (>99.9th centile) -> 2nd IRT at 21-28 days
Current UK screening for IMDs
PKU from 1969
Congenital hypothyroidism 1970
Sickle cell disease 2006
CF 2007
Medium chain AcylCoA dehydrogenase deficiency (MCADD) 2009 (fatty acid oxidation disorder)
MCADD
cause of cot death;
in between feeding, baby cannot break down fats, dies of hypoglycaemia
MCADD screening
using acylcarnitine levels by tandem mass spec
incidence 1:10,000
treatable: make sure babies never become hypoglycaemic
Homocystinuria
failure of remethylation of homocysteine
causes: lens dislocation, mental retardation, thromboembolism from an early age
currently screened for in Wales and in trial in UK to decide if it should be added
amino acid disorder
Urea cycle defects
7 enzymes so 7 recorded defects
Also includes 3 conditions: Lysinuric protein intolerance, HHH, Citrullinaemia type II
all autosomal recessive except OTC (X-linked)
Urea cycle begins with ammonia and ends with urea so any defect will result in hyperammonaemia (ammonia is very toxic)
ammonia > 300 micromol/L results in hyperammonaemic coma (1 day in this condition results in very low IQ)
Incidence: 1:30,000
Testing after discovering hyperammonaemia
Plasma glutamine will be high as well as other plasma amino acids as your body tries to remove the excessive ammonia by adding an ammonium group to glutamate (to make glutamine) and other amino acids
Urine orotic acid will also be raised
Treating hyperammonaemia
Remove ammonia by giving sodium benzoate or sodium phenylacetate or dialyse
Reduce ammonia production: low protein diet
Symptoms of hyperammonaemia
Nausea & Vomiting without diarrhoea
Protein intolerance/avoidance/changes in diet
long term neurological/psychiatric illness (tactile hallucinations/ADHD) / neurological encephalopathy
dehydration
respiratory alkalosis
Organic acidurias
hyperammonaemia with metabolic acidosis and high anion gap
most important involve complex metabolism of branched chain amino acids (leucine, isoleucine and valine)
Isovaleric acidaemia
Defect in isovaleryl CoA dehydrogenase in cycle of leucine breakdown
build of isovaleryl CoA so exported as isovaleryl carnitine and excreted as isovaleryl glycine and 3OH-isovaleric acid (has a cheesy or sweaty smell)
Organic aciduria presentation
Unusual odour (person or urine)
lethargy
feeding problems
truncal hypotonia / limb hypertonia, myoclonic jerks
hyperammonaemia with metabolic acidosis and high anion gap not caused by lactate
hypocalcaemia
neutropenia, thrombopenia, pancytopenia
Chronic intermittent forms of organic acidurias
recurrent episodes of ketoacidotic coma, cerebral abnormalities
Reye syndrome: vomiting, lethargy, increasing confusion, seizures, decerebration, respiratory arrest. Triggered by: salicylates, antiemetics, valproate
Reye syndrome metabolic screen
plasma ammonia
plasma/urine amino acid
urine organic acids
plasma/blood glucose and lactate
(all of these during acute episode)
blood spot carnitine profile (stays abnormal even in remission)
Mitochondrial fatty acid beta oxidation defects
hypoketotic hypoglycaemia (normally if hypoglycaemic, should have high ketones to compensate)
hepatomegaly and cardiomyopathy
Tests for Mitochondrial fatty acid beta oxidation defects
Blood ketones
urine organic acids
blood spot acylcarnitine profile
Galactosaemia
3 known disorders of galactose metabolism
Most severe and common is galactose-1-phosphate uridyl transferase disorder (Gal-1-PUT)
raised gal-1-phosphate causes liver and kidney disease
not screened for as more likely that patients will present early
treatment: galactose-free diet
Galactosaemia presentation
vomiting
diarrhoea
hepatomegaly
hypoglycaemia
sepsis (E. coli because galactose-1-phosphate inhibits immune responses)
conjugate hyperbilirubinaemia (always pathological in infant)
Untreated galactosaemia
galactitiol is formed by the action of aldolase on gal-1-phospgate leading to bilateral cataracts
Testing for galactosaemia
Urine reducing substances (pick up huge amounts of galactase)
Red cell Gal-1-PUT
Glycogen storage disease type 1
also called von gierke’s
glycogen cannot be broken down as glucose-6-phosphatase is defective so G6P cannot be exported and therefore builds up in tissue making it a storage disease (glycogen is excessively stored in tissue)
most severe of GSDs
Glycogen storage disease type 1 presentation
hepatomegaly
nephromegaly
hypoglycaemia
lactic acidosis
Mitochondrial disorders
heteroplasmy (high turnover) means that clinical manifestations become evident at a certain threshold of mutant DNA
mtDNA is maternally inherited but nuclear genomes play a huge role in mitochondrial function - transporting and assembly
therefore disorders can present in any organ at any age in any form of inheritance
Organs affected by mitochondrial disorders
defective ATP production leads multisystem disease especially affecting organs with a high energy requirement:
brain, muscle, kidney, retina, endocrine organs
Mitochondrial disorders at birth
Barth syndrome (cardiomyopathy, neutropenia, myopathy)
Mitochondrial disorders at age 5-15
MELAS (mitochondrial encephalopathy, lactic acidosis and stroke-like episodes)
Mitochondrial disorders at age 12-30
Kearns-Sayre (chronic progressive external ophthalmoplegia, retinopathy, deafness, ataxia)
Investigating mitochondrial disorders
Elevated lactate (alanine) after periods of fasting
CSF lactate/pyruvate (deproteinised at bedside so inconvenient)
CSF protein (raised in Kearns-Sayre syndrome)
CK elevation (unexplained)
Muscle biopsy (looking for ragged red fibres or measuring oxphos compounds)
Mitochondrial DNA analysis (not in children)
Common problems in low-birth weight infants
respiratory distress syndrome (RDS) - can lead to retinopathy of prematurity (ROP) due to low oxygen
intraventricular haemorrhage (IVH)
patent ductus arteriosus (PDA)
necrotising enterocolitis (NEC)
Necrotising enterocolitis
inflammation of the bowel wall progressing to necrosis and perforation
Signs/Symptoms: bloody stools, abdominal distension, intramural air on abdo x-ray
Renal function in gestation
develop from week 6
start producing urine from week 10
full complement from week 36
functional maturity of GFR not reached until 2 years of age
Renal function in newborns
newborns are very susceptible to acidosis as they cannot exchange hydrogen due to low availability of sodium because of slow excretion (small surface area of glomerulus) and short proximal tubule means there is a lower reabsorptive capability of bicarbonate
loops of henle and distal collecting ducts are short so osmalility cannot reach above 700
distal tubule is quite unresponsive to aldosterone leading to a persistent loss of sodium (1.8 mmol/kg/day) therefore reduced potential potassium excretion
Water redistribution in neonates
in first week of life ECF falls due to decreased pulmonary resistance and release of ANP
therefore all babies lose weight in first week of life - upto 10% of birthweight is acceptable and will regain day 7-10
ECF falls by 40ml/Kg in full term and 100ml/Kg in pre-term
Requirements for healthy neonates
require high sodium and potassium (2-3 mmol/kg/day)
only give potassium after urine output of > 1ml/kg/h is established otherwise you risk hypernatraemia
Electrolyte disturbance in neonates
High insensible water loss due to: high surface area, high skin blood flow, high metabolic/respiratory rate, high transepidermal fluid loss
Drugs: bicarbonate for acidosis (give sodium bicarb so high sodium content), antibiotics (have sodium), caffeine/theophylline for apnoea (increases renal sodium losses), indomethacin for PDA (causes oliguria)
Lack of growth means hypernatraemia
Hypernatraemia in neonate
uncommon after 2 weeks of age, usually associated with dehydration
repeated hypernatraemia without obvious cause could indicate salt poisoning or osmoregulatory dysfunction (both rare but should be considered) - can be diagnosed via routine measurement of urea, creatinine and electrolytes on paired urine and plasma
Hyponatraemia in neonates
relatively rare
caused by congenital adrenal hyperplasia: pregnenolone is not converted into aldosterone so there is salt loss (21-hydroxylase deficiency), nb: also decreased cortisol
Increased precursors: pregnenolone and 17-OH progesterone
Congenital Adrenal hyperplasia (CAH) presentation
hyponatraemia with hyperkalaemia and marked volume depletion
elevated precursors lead to high levels of androgens leading to ambiguous genitalia in female neonates (male neonates often die in salt-losing crisis)
growth acceleration
Hyperbilirubinaemia in neonates
High level of synthesis (rbc breakdown)
low rate of transport into liver
enhanced enterohepatic circulation (even if bilirubin gets into liver, gets exported quickly)
hyperbilirubinaemia in first 10 days of life very common but bilirubin is unconjugated
free bilirubin (>340 cannot be bound by albumin) crosses the blood-brain barrier and causes kernicterus (bilirubin encephalopathy) -> long-term neurological defects
Treating neonatal hyperbilirubinaemia
In full-term: phototherapy (>340), exchange transfusion (>450)
In pre-term: phototherapy (>120), exchange transfusion (>230) because albumin is lower and BBB is more leaky so more susceptible
Causes of hyperbilirubinaemia in neonate
haemolytic disease (ABO, rhesus etc)
G-6-PD deficiency
Crigler-Najjar syndrome
Prolonged jaundice in neonates
jaundice that lasts more than 14 days in term babies and more than 21 days in preterm babes
Causes: prenatal infection/sepsis/hepatitis, hypothyroidism (screened day 6-8), breast milk jaundice
Conjugated hyperbilirubinaemia in neonates
> 20 micromol/L
always pathological
most common cause: biliary atresia & choledocal cyst, often associated with cardiac malformations, polysplenia, situs inversus, early surgery (before 6 months of age) is essential
Other most common cause ascending cholangitis in babies who have been on total parenteral nutrition caused by lipid content
Calcium & phosphate levels in neonates
calcium levels fall after birth so reference range for hypocalcaemia is lower than in adult
phosphate reference ranges higher as babies are good at reabsorbing phosphate
Osteopenia of prematurity
Fraying, splaying and cupping of long bones (on x-ray)
if untreated can progress to flail chest
biochemistry: calcium within reference range (last thing to go), low phosphate < 1mmol/L, alk phos > 1200 U/L, vitamin D rarely measured in neonates and osteopenia is due to susbtrate deficiency
Treatment: phosphate / calcium supplements but not at same time (may give 1 alpha calcidol)
Rickets
osteopenia due to deficient activity of vitamin D
frontal bossing, bow legs / knock knees, muscular hypotonia, abdominal laxity
alternative presentation (more common now): tetany/hypocalcaemic seizure, hypocalcaemic cardiomyopathy
Genetic causes of rickets
pseudo vitamin D deficiency I - defective renal hydroxylation
pseudo vitamin D deficiency II - receptor defect
familial hypophosphataemias - low tubular maximum reabsorption of phosphate, raised urine phosphoethanolamine
What are purines?
ubiquitous biomolecules
Adenosine & Guanine (Inosine = intermediate)
genetic code A & G
second messengers for hormone action (eg. cAMP)
Energy transfer eg (ATP)
Purine catabolism
purines are broken down into hypo-xanthine
hypo-xanthine is broken down into xanthine by xanthine oxidase
xanthine is broken down into urate by xanthine oxidase
urate is broken down into allantoin by uricase
allantoin is highly soluble and excreted in urine therefore this process does not cause problems
most humans have an inactive coding gene for uricase meaning we have to excrete urate rather than allantoin which is not very soluble and circulates in the blood at a concentration similar to its solubility limit (means it can easily crystalise and form gout) - urate precipitates at lower temperature hence why extremities are more likely to be affected by gout
Fractional excretion of uric acid (FEUA)
approx 10%
other 90% is reabsorbed in nephrons to prevent oxidative stress (urate is important anti-oxidant)
How to make purines?
De novo synthesis (lots of energy needed, not used unless utterly mandated by high demand)
Salvage pathway - recycling (highly energy efficient so used whereever possible, so predominates in all cells bone marrow [frantically synthesising new cells all the time so salvage pathway alone is inadequate])
Purine de-novo synthesis rate-limiting step
catalysed by PAT
under feedback inhibition control by ANP and GNP
accelerated by build up of PPRP
HPRT/HGPRT
hypo-xanthine guanine phosphoribosyltransferase
scoops up partially catabolised purines and brings them up to beginning of metabolic pathway (transfer hypo-xanthine into inosinic acid and guanine into guanylic acid)
main enzyme of salvage pathway
Lesch Nyhan syndrome
absolute HGPRT deficiency
normal at birth
developmental delay apparent at 6/12
hyperuricaemia (–> gout)
choreiform movements (1 year) - abnormality in basal ganglion function
spasticity, mental retardation
self mutilation (85%) aged 1-6 (esp biting lips and biting digits so hard that seriously injure themselves and bleed)
X-linked disease, almost exclusively affects males
effect of HGPRT deficiency metabolically
no recycling of hypo-xanthine into inosinic acid (INP) and guanine into guanylic acid (GNP) therefore no negative feedback on PAT causing increased production of INP and GNP by de-novo synthetic pathway.
INP and GNP get metabolised and there is a build-up of urate.
(de-novo pathway is in overdrive)
Gout
crystal arthropathy: monosodium urate crystals
crystal are very intense inflammatory stimuli
very painful
can be acute (podagra) or chronic (tophaceous)
chronic: deposition in soft tissue peri-articular (next to joints) and ear lobes
can progress from acute to chronic
males prevalence 0.5-3%
females prevalence 0.1-0.6%
(post-pubertal males and post-menopausal females)
Acute gout clinical features
rapid build of pain
exquisite pain
affected joint is red, hot and swollen
1st MTP joint is first site in 50% (involved in 90% overall)
Acute gout management (reducing inflammation)
NSAIDs
colchicine (inhibits mircotubule assembly by inhibiting polymerisation, cell turnover is suppressed as mitosis is inhibited, works in gout by reducing motility of neutrophils so unable to migrate into joint and cause inflammation)
glucocorticoids (systemic or intra-articular)
(do not attempt to modify plasma urate concentrations)
Chronic gout management (managing hyperuricaemia)
drink lots of water
reverse factors putting up urate (eg stop thiazide diuretics)
reduce synthesis with allopurinol
increase renal excretion with probenecid (uricosuric)
allopurinol
inhibits xanthine oxidase
thereby inhibits production of urate
Uricosuric drugs
increased FEUA
enhance tubular excretion of urate (loop of henle)
Allopurinol side effects
interacts with azathioprine (makes it more toxic on bone marrow) - never give both together
azathioprine is metabolised into mercaptopurine and then into thioinosinate which interferes with purine metabolism
allopurinol makes the mercaptopurine last longer (inhibiting its metabolism)
Diagnosis of gout
tap effusion
view under polarised light
use red filter
looking for birefringence
birefringence = ability of crystal to rotate light
gout: negatively birefringent (appear blue perpendicular to red filter axis and yellow parallel)
pseudogout: positively birefringent, pyrophosphate (blue parallel to red filter axis, yellow perpendicular)
Pseudogout
occurs in patients with osteoarthritis
pyrophosphate crystals
self limiting 1-3 weeks
Roles of calcium
skeleton (99% of body calcium)
metabolic: action potentials and IC signalling
Calcium in serum
3 forms:
1. free (ionised) 50% - biologically active
2. protein-bound 40% - bound to albumin
3. complexed 10% - citrate/phosphate
reported calcium is corrected for albumin
= serum calcium + 0.02*(40-serum albumin in g/L) - if albumin is normal corrected and total will be the same
total serum calcium: 2.2-2.6 mmol/L (can be affected by amount of albumin hence correction)
ionised calcium can also be measured
Circulating calcium
important for normal nerve and muscle function
plasma conc must be maintained despite calcium and vitamin d deficiency
chronic calcium deficiency results in loss of calcium from in bone in order to maintain circulating calcium (–> osteoporosis)
Calcium homeostasis
low Ca detected by parathyroid gland which will release PTH
PTH increases Ca from 3 sources:
bone (resorption)
gut (absorption increased by 1,25 OH vit D - also increases phosphate absorption)
kidney (resorption and renal 1 alpha hydroxylase activation - increased 1,25 OH vit D)
PTH
84 aa protein
only released from parathyroids (unless ectopic production by tumour)
bone and ca resorption
stimulates 1,25 OH vit d synthesis (hydroxylation)
stimulates renal phosphate wasting (phosphate trashing hormone)
Vit D synthesis
7-dehydrocholesterol converted to cholecalciferol (vit D3) by sunlight in skin
(cholecalciferol is inactive and large amounts are not dangerous - bought OTC)
cholecalciferol stored in liver and then converted to 25-hydroxycholecalciferol (25-OH D3) in liver by 25 hydroxylase
converted to 1,25-dihydroxycholecalciferol (1,25-(OH)2 D3 aka calcitriol) in kidney by 1 alpha hydroxylase- rate-limiting step, only carried out in presence of PTH
calcitriol is physiologically active form (drug - given in kidney failure and regularly measured)
Ergocalciferol
plant product
vit d2
can be taken as supplement (same effect as cholecalciferol)
Vitamin d blood test
measures stored vitamin d in form of 25-hydroxy vitamin D
(active form [calcitriol] is made and immediately used up so not measured)
1 alpha hydroxylase
rarely can be expressed in lung cells of sarcoid tissue
usually affects resp but can sometimes activate vitamin D and cause hypercalcaemia
roles of 1,25 (OH)2 vit D (calcitriol)
increases calcium and phosphate absorption in gut
critical for bone formation
Also: vit d receptor controls many genes eg. for cell proliferation and immune system –> deficiency associated with cancer, autoimmune disease, metabolic syndrome (not causative)
Role of skeleton
structural framework - strong, relatively lightweight, mobile, protects vital organs, capable of orderly growth and remodelling (with use)
metabolic role in calcium homeostasis - reservoir for calcium, phosphate, magnesium
metabolic bone diseases
osteoporosis
osteomalacia
paget’s disease
parathyroid bone disease
renal osteodystrophy
vitamin d deficiency
defective bone mineralisation
childhood -> rickets
adulthood -> osteomalacia (not same as osteoporosis)
> 50% of adults in the UK have deficiency but not necessarily osteomalacia - take supplements, 16% have severe deficiency during winter and spring
risk factors: lack of sunlight exposure, dark skin, dietary, malabsorption
clinical features of osteomalacia
bone and muscle pain
increased fracture risk
biochem: low Ca and low phosphate with raised ALP (osteoblasts trying to rebuild bone) (other LFTs normal)
Looser’s zone (pseudofractures - looks like fracture but doesn’t go through bone completely)
osteomalacia in mother increases risk of rickets in child
clinical features of rickets
bowed legs
costochondral swelling
widened epiphyses at wrists
myopathy –> unusual gait
Osteomalacia key facts
bone is demineralised
caused by:
vit d deficiency
renal failure
lack of sunlight
anticonvulsants in children induce breakdown of vit d (anticonvulsant rickets) - can also happen in adults but they have sufficient reserves
phytic acid (in chappatis) chelates vitamin D
uncalficied osteoid cells if biopsy bone
Osteoporosis
causes pathological fracture
occurring more often as people live longer (becoming more common)
loss of bone mass due to reduced use (reduced bone density but normal mineralisation)
bone slowly lost after age 20
residual bone is normal in structure
biochem: normal ca and normal phosphate
asymptomatic until fracture (typically: neck of femur and, vertebral, Colle’s [wrist]) - too late
Causes of osteoporosis
age
cushing’s (causes colles fractures more commonly)
hyperprolactinaemia
thyrotoxicosis
steroids (causes vertebral fractures more commonly)
menopause
childhood illness (peak bone density not reached)
testosterone deficiency
liver cirrhosis
acromegaly
dietary - protein, calcium, vitamin C (scurvy) deficiency
alcohol
smoking
sedentary lifestyle
hyponatraemia
serum sodium < 135 mmol/L
commonest electrolyte abnormality in hospitalised patients
underlying pathogenesis of hyponatraemia
= water problem (not salt problem)
increased extracellular water
water balance controlled by ADH (vasopressin) - released from posterior pituitary and acts on distal nephrons of kidney, inserts aquaporin-2 and increases water retention
therefore underlying pathogenesis is excess ADH
ADH
acts on V2 receptors of collecting duct
insertion of aquaporin-2
V1 receptors: vascular smooth muscle, vasoconstriction (higher concentrations) = vasopressin
stimuli for ADH secretion
increased serum osmolality (mediated by hypothalamic osmoreceptors)
decreased blood volume/pressure (mediated by baroreceptors in carotids, atria, aorta)